Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, LLC in July 2020. Virios Therapeutics, LLC was founded in 2012 and is headquartered in Alpharetta, Georgia.